Johnson & Johnson halts COVID-19 vaccine trials after unexplained illness

0 29

Johnson & Johnson (NYSE:JNJ) announced it has paused dosing in all its COVID-19 vaccine candidate clinical trials after an unexplained illness in a study participant.


It is not clear whether the individual received a study treatment or a placebo.


READ: The runners in the COVID-19 vaccine race


The pharma giant stressed such adverse events are an expected part of any clinical study, especially large studies and there will be a careful review of all of the medical information before deciding whether to restart the study.


The phase III study of the jab is involving up to 60,000 participants in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and the US.


“We must respect this participant’s privacy,” the US company noted, “we’re also learning more about this participant’s illness, and it’s important to have all the facts before we share additional information.”

Leave A Reply

Your email address will not be published.